Published • loading... • Updated
First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Summary by Clinical Trials Arena
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
Verdict HospitalReposted by 
Clinical Trials Arena
Clinical Trials ArenaFirst healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial
Triveni Bio has dosed the first healthy volunteers in its Phase I study of TRIV-573, a half-life extended bispecific antibody aimed at KLK5/7 and IL-13.The post First healthy volunteers receive TRIV-573 doses in Triveni Bio’s Phase I trial appeared first on Hospital Management.
Coverage Details
Total News Sources2
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
